Drugs / SJ-Neo006
last change Dec 2025 re-read 2 minutes ago

SJ-Neo006

Messenger RNA (mRNA)

Developed for
malignant pancreatic neoplasm
Investigated by
Jiangsu Synthgene Biotechnology Co.Ltd. · Jinling Hospital, China

Trials 1 · a red edge is where a trial was stopped

20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT06326736 Apr 2024 → Dec 2025 overdue malignant pancreatic neoplasm Jinling Hospital, China Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SJ-Neo006 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06326736
Modality Messenger RNA (mRNA) “Neoantigen mRNA Vaccines” NCT06326736